In the ELIXA trial (Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome), the only GLP-1 RA trial conducted in a post–acute coronary syndrome setting, it was observed that the use of lixisenatide was not superior to placebo in reducing the risk of MACE (80). Here, GLP1R is linked to type 2 diabetes mellitus.